Dr. Andino on the use of telehealth over the course of the COVID-19 pandemic
“With more people using [telehealth], with more people essentially forced by the pandemic to have to offer care at least at some point virtually, there is comfort and…more interest in ensuring that it remains an option,” says Juan José Andino, MD.
In this video, Juan José Andino, MD, discusses the increased use of telehealth visits in urological care and what changes he has observed in telemedicine over the course of the pandemic. Andino is a urology resident at the University of Michigan Hospital-Michigan Medicine, Ann Arbor.
Dr. Lacouture on managing dermatological adverse events with apalutamide in prostate cancer
February 7th 2022To investigate the severity and prevalence of dermatologic adverse events associated with apalutamide, Mario E. Lacouture, MD, and investigators conducted a study that will help to manage and counsel patients with prostate cancer in the future, especially with the expanded approval of apalutamide in this space.
How appropriate use criteria for PSMA-PET imaging optimize patient care
February 2nd 2022In a recent interview, Hossein Jadvar, MD, PhD, discussed what the appropriate use criteria consist of for prostate-specific membrane antigen (PSMA)-PET imaging, and why these criteria are vital in ensuring the individualized care of patients.
Dr. Padmanabhan discusses impact of COVID-19
June 11th 2020Urology Times® Editorial Council Member Priya Padmanabhan, MD, MPH, professor of urology at Oakland University William Beaumont School of Medicine, Royal Oak, Michigan, discusses how she has been affected by the coronavirus disease 2019 (COVID-19) pandemic.
